Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | CA12 | O43570 | 10/20 | 0.49 |
| ▸ | CA2 | P00918 | 10/20 | 0.49 |
| ▸ | CA1 | P00915 | 9/20 | 0.49 |
| ▸ | CA9 | Q16790 | 8/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25716867 | 0.87 | LMNA (0.67) | LMNACA12CA2CA1CA9 | |
| SCHEMBL16392625 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL23626630 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL21366081 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL25480951 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL24378476 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL18102369 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL14010273 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL16392612 | 0.87 | LMNA (0.57) | LMNACA12CA2CA1CA9 | |
| SCHEMBL21137853 | 0.86 | LMNA (0.51) | LMNACA12CA2CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2023-09-14 | — | — | US | disclosed |
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION (US) | 2023-04-25 | — | — | US | disclosed |
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-05-25 | — | — | US | disclosed |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | THE GENERAL HOSPITAL CORPORATION | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634448-B2 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | LMNA 3593/4885CA12 252/4885CA2 2104/4885 |
| US-11014953-B2 | Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting | GPI, SLC2A1, SLC2A4 | LMNA 3922/4885CA12 433/4885CA2 1541/4885 |
| US-20170362266-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | LMNA 3593/4885CA12 252/4885CA2 2104/4885 |
| US-20230287030-A1 | Metabolic labeling and molecular enhancement of biological materials using bioorthogonal reactions | GALNT14, NEU4, CSGALNACT1 | LMNA 3593/4885CA12 252/4885CA2 2104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.